Literature DB >> 3899002

Comparison of ceftazidime with cefamandole for therapy of community-acquired pneumonia.

J C Engle, P W Lifland, C J Schleupner.   

Abstract

Ceftazidime and cefamandole were compared in the treatment of pneumonia. The median MIC of ceftazidime for all Streptococcus pneumoniae (n = 17) and Haemophilus influenzae (n = 10) isolates was 0.125 microgram/ml. All other isolates were inhibited by less than 0.5 microgram of ceftazidime per ml, with the exception of a group B streptococcus (MIC = 4 micrograms/ml). Satisfactory clinical responses were observed in 91% (20 of 22) of cefamandole-treated patients and 85% (17 of 20) of ceftazidime-treated patients.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3899002      PMCID: PMC176328          DOI: 10.1128/AAC.28.1.146

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  32 in total

1.  Pharmacokinetics of cefotaxime.

Authors:  K P Fu; P Aswapokee; I Ho; C Matthijssen; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1979-11       Impact factor: 5.191

2.  Effect of cefamandole nafate on blood coagulation and platelet function.

Authors:  G M Custer; B R Briggs; R E Smith
Journal:  Antimicrob Agents Chemother       Date:  1979-12       Impact factor: 5.191

3.  Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime.

Authors:  R Lüthy; J Blaser; A Bonetti; H Simmen; R Wise; W Siegenthaler
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

4.  Comparative antipseudomonal activity of some newer beta-lactam agents.

Authors:  D Greenwood; A Eley
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

5.  Ceftazidime--a new extended-spectrum cephalosporin.

Authors:  D I Gozzard; A M Geddes; I D Farrell; S J Eykyn; I Phillips; R Wise; R M Brown
Journal:  Lancet       Date:  1982-05-22       Impact factor: 79.321

6.  Comparison of in vitro activities of eight beta-lactamase-stable cephalosporins against beta-lactamase-producing gram-negative bacilli.

Authors:  L Verbist
Journal:  Antimicrob Agents Chemother       Date:  1981-03       Impact factor: 5.191

7.  Clinical evaluation of cefotaxime for therapy of lower respiratory tract infections.

Authors:  C J Schleupner; J C Engle
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

8.  Resistance to cefamandole: a collaborative study of emerging clinical problems.

Authors:  C C Sanders; R C Moellering; R R Martin; R L Perkins; D G Strike; T D Gootz; W E Sanders
Journal:  J Infect Dis       Date:  1982-01       Impact factor: 5.226

9.  GR 20263, a new broad-spectrum cephalosporin with anti-pseudomonal activity.

Authors:  C H O'Callaghan; P Acred; P B Harper; D M Ryan; S M Kirby; S M Harding
Journal:  Antimicrob Agents Chemother       Date:  1980-05       Impact factor: 5.191

10.  GR-20263: a new aminothiazolyl cephalosporin with high activity against Pseudomonas and Enterobacteriaceae.

Authors:  L Verbist; J Verhaegen
Journal:  Antimicrob Agents Chemother       Date:  1980-05       Impact factor: 5.191

View more
  4 in total

Review 1.  Treatment of respiratory tract infections with cephalosporin antibiotics.

Authors:  R Finch
Journal:  Drugs       Date:  1987       Impact factor: 9.546

2.  Ampicillin versus cefamandole as initial therapy for community-acquired pneumonia.

Authors:  D J Weber; S B Calderwood; A W Karchmer; J E Pennington
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

3.  Randomized comparative trial with ampicillin/sulbactam versus cefamandole in the therapy of community acquired pneumonia.

Authors:  D Williams; M Perri; M J Zervos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-04       Impact factor: 3.267

Review 4.  Ceftazidime. An update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  C P Rains; H M Bryson; D H Peters
Journal:  Drugs       Date:  1995-04       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.